This study is looking at how well a medicine called efanesoctocog alfa helps people with moderate to severe hemophilia A (a bleeding disorder where your blood doesn't clot properly) who have swelling in their joints. The study will give efanesoctocog alfa once a week through an IV (into a vein) for about 12 months. Researchers want to see if this treatment improves joint swelling, which will be measured using a special ultrasound test. You can join if you are 12 years or older and have moderate to severe hemophilia A. The study plans to enroll 35 participants, but its current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 35 participants.

What's involved

You would receive efanesoctocog alfa once a week through an IV for approximately 12 months. Your joint swelling will be checked with an ultrasound during this time.

Compensation

Not stated in the trial record.

Follow-up

Your joints will be checked for improvement from the start of the study up to Week 52 (about 12 months).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.